Longboard Pharmaceuticals

NEWS

Pictured: Bar and line graphs showing increasing t

Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering

Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.

January 3, 2024

2 min read

Tristan Manalac

IN THE PRESS

Biotech Beach

Longboard Pharmaceuticals Announces Commencement of Public Offering of Common Stock - February 07, 2023

February 7, 2023

4 min read

Drug Development

Longboard Pharmaceuticals Announces Positive Topline Data from a Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

December 5, 2022

9 min read

Biotech Beach

Longboard Pharmaceuticals’ Presence at American Epilepsy Society (AES) Annual Meeting Reinforces Ongoing Commitment to the Rare Epilepsy Community

November 29, 2022

4 min read

Biotech Beach

Longboard Pharmaceuticals to Present at Guggenheim’s Healthcare Talks 4th Annual Immunology and Neurology Day

November 8, 2022

2 min read

Business

Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2022 Financial Results

November 3, 2022

9 min read

Biotech Beach

Longboard Pharmaceuticals to Participate in the Cantor Neurology & Psychiatry Conference

September 29, 2022

2 min read

Biotech Beach

Longboard Pharmaceuticals to Participate in Upcoming September 2022 Investor Conferences

September 1, 2022

2 min read

Business

Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2022 Financial Results

August 4, 2022

9 min read

Biotech Beach

Longboard Pharmaceuticals to Present at the 2022 Wedbush PacGrow Healthcare Virtual Conference

August 3, 2022

2 min read

Biotech Beach

Longboard Pharmaceuticals to Present at the JMP Securities 2022 Life Sciences Conference on June 15

June 7, 2022

2 min read

JOBS